CTAD 2023: Medical Centers Adapt To Leqembi Testing, Monitoring Requirements

Questions Remain Around Long-Term Use

Neurologists shared their health care facilities’ protocols as they begin treating Alzheimer’s patients with the first anti-amyloid treatment to win both US FDA approval and Medicare coverage – Eisai/Biogen’s Leqembi. 

PET CT scan of Human Brain (Axial view Positron Emission Tomography)
PET scans, MRI monitoring and infusions complicate treatment with anti-amyloid antibodies • Source: Shutterstock

Neurologists at the Clinical Trials on Alzheimer’s Disease (CTAD) annual meeting welcomed the introduction of the first US Food and Drug Administration-approved anti-amyloid antibody for early Alzheimer’s disease to also win Medicare coverage – Eisai Co., Ltd./Biogen, Inc.’s Leqembi (lecanemab) – but also noted the thoughtful process their affiliated health care centers are undertaking to make sure the therapy gets to appropriate patients.

Key Takeaways
  • Treating early Alzheimer’s disease with anti-amyloid therapies, like Eisai/Biogen’s Leqembi, involves PET scans, MRI monitoring, genetic testing and infusion of the medicines – a complicated process for doctors, health care systems and their patients.

The FDA converted Leqembi’s accelerated approval to a traditional approval on 6 July, and the Centers for Medicare and Medicaid...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

 

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.

Insmed’s New R&D Site Focused On ‘Synthetic Rescue’

 

A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

More from Therapy Areas

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.